Tag: Apellis Pharmaceuticals

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Apellis Pharmaceuticals

Apellis Pharmaceuticals (NASDAQ:APLS) PT Set at $52.00 by Cantor Fitzgerald

Added to Collection on: 2018-08-08 22:15:06

Tags for this article:

Money
Finance
Economy
Stock
Short
Corporate finance
Financial regulation
Investment management
Apellis Pharmaceuticals

Click the tags to see associated articles and topics

View Article Details
Apellis Pharmaceuticals (NASDAQ:APLS) Lifted to “Buy” at B. Riley

Added to Collection on: 2018-08-16 16:37:30

Tags for this article:

Money
Finance
Economy
Stock market
Stock
Short
Corporate finance
Price?earnings ratio
Financial regulation
Apellis Pharmaceuticals

Click the tags to see associated articles and topics

View Article Details
Cantor Fitzgerald Raises Apellis Pharmaceuticals (APLS) Price Target to $53.00

Added to Collection on: 2018-09-01 04:26:15

Tags for this article:

Biotechnology
Industries
Life Sciences
Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc.
Price–earnings ratio

Click the tags to see associated articles and topics

View Article Details
Apellis Pharmaceuticals (APLS) Price Target Raised to $40.00

Added to Collection on: 2018-09-15 22:26:15

Tags for this article:

Biotechnology
Specialty drugs
Sofinnova
Industries
Life Sciences
Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc.

Click the tags to see associated articles and topics

View Article Details
Cantor Fitzgerald Analysts Give Apellis Pharmaceuticals (NASDAQ:APLS) a $53.00 Price Target

Added to Collection on: 2018-09-14 19:00:22

Tags for this article:

Biotechnology
Specialty drugs
Life Sciences
Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc.

Click the tags to see associated articles and topics

View Article Details
Geographic Atrophy Pipeline Report 2021: Therapeutic Evaluation, Drug Profiles, Unmet Needs ...

Added to Collection on: 2021-02-10 01:30:00

Tags for this article:

Geographic atrophy
Organ systems
Macular degeneration
NGM BIOPHARMACEUTICALS
Apellis Pharmaceuticals

Click the tags to see associated articles and topics

View Article Details
Beam, Apellis partner in deal to expand gene editing's reach

Added to Collection on: 2021-06-30 20:42:54

Tags for this article:

Branches of biology
Biology
Life Sciences
Biotechnology
Genetic engineering
Emerging technologies
Molecular biology
Biological engineering
Macular degeneration
CRISPR
Complement factor I
Thalassemia
Apellis Pharmaceuticals

Click the tags to see associated articles and topics

View Article Details
Apellis, Beam ink $75M deal to bring gene-editing meds to complement diseases

Added to Collection on: 2021-06-30 20:15:00

Tags for this article:

Branches of biology
Biology
Articles
Emerging technologies
Genetic engineering
Biotechnology
Molecular biology
Genome editing
Intellia Therapeutics
PCSK9
Cholesterol
CRISPR
Apellis Pharmaceuticals

Click the tags to see associated articles and topics

View Article Details
Comparing the efficacy of pegcetacoplan and avacincaptad pegol in patients with GA

Added to Collection on: 2023-12-30 17:05:23

Tags for this article:

Complement system
Clinical research
Orphan drugs
Immunosuppressants
Pegcetacoplan
Biotechnology
Geographic atrophy
Pegol
Avacincaptad pegol
Clinical trial
Inclusion and exclusion criteria
Paul Hahn
Apellis Pharmaceuticals

Click the tags to see associated articles and topics

View Article Details
JPMorgan Raises Price Target for Apellis to $37, Maintains Overweight Rating - AInvest

Added to Collection on: 2025-08-05 07:46:20

Tags for this article:

Financial economics
Profit
Profit margin
Valuation
Membranoproliferative glomerulonephritis
Pharmaceutical industry in China
Swedish Orphan Biovitrum
Apellis Pharmaceuticals

Click the tags to see associated articles and topics

View Article Details
Book a Demo